# Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

> **NCT05234775** · PHASE3 · COMPLETED · sponsor: **LIB Therapeutics LLC** · enrollment: 22 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** lerodalcibep

## Key facts

- **NCT ID:** NCT05234775
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-28
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-07-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234775, "Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05234775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*